The companies will explore the use of MGTA-117, which is currently in preclinical IND-enabling studies as a conditioning regimen for patients receiving gene therapy designed to be less toxic than the current standard of chemotherapy or radiation.
The company is developing the drug, MGTA-145 as a one-day stem cell-mobilization product, compared with current standard G-CSF, which must be administered over several days and is associated with severe side effects.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
A company analysis deemed the patient's myelodysplastic syndrome was unrelated to LentiGlobin, but a news report indicated it may have stemmed from the conditioning regimen used in the trial.